抗-HBc定量测定在乙型肝炎病毒慢性感染性疾病中的应用

doi:10.16352/j.issn.1001-6325.2022.05.010

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (5): 804-808.doi: 10.16352/j.issn.1001-6325.2022.05.010

抗-HBc定量测定在乙型肝炎病毒慢性感染性疾病中的应用

杜心怡¹, 毛小荣^2*, 李俊峰²

1.兰州大学第一临床医学院, 甘肃兰州 730000;
2.兰州大学第一医院感染科, 甘肃兰州 730000

收稿日期:2021-06-23 修回日期:2021-11-11 出版日期:2022-05-05 发布日期:2022-04-28
通讯作者: * mxr2013@126.com
基金资助:
国家自然科学基金(81800528);甘肃省自然科学基金(20JR5RA364);甘肃省重点研发计划(21YF5FA121); 甘肃省感染肝病临床医学研究中心(21JR7RA392)

Application of anti-HBc quantitative examination in clinical management of chronic hepatitis B virus infection

DU Xin-yi¹, MAO Xiao-rong^2*, LI Jun-feng²

1. The First Clinical Medical College, Lanzhou University, Lanzhou 730000;
2. Department of Infection, the First Hospital, Lanzhou University, Lanzhou 730000, China

Received:2021-06-23 Revised:2021-11-11 Online:2022-05-05 Published:2022-04-28
Contact: * mxr2013@126.com

摘要/Abstract

摘要： 乙肝病毒核心抗体(抗-HBc)与机体免疫相关,在现症及既往乙型肝炎病毒(HBV)感染者血清中均可测得,其在HBV自然史的判断及治疗策略中可发挥巨大作用。HBV感染慢性化与肝内共价闭合环状DNA(cccDNA)活跃转录和持续存在密切相关;抗-HBc定量与cccDNA水平有较好相关性,可作为综合评价HBV感染性疾病的一项指标。

关键词: 乙型肝炎病毒(HBV), 共价闭合环状DNA, 乙肝病毒核心抗体定量, 慢性感染

Abstract: The quantification of hepatitis B virus(HBV) core antibody (anti-HBc) is related to host immunity and can be detected in the serum of patients with current or past infections. The antibody against core antigen of HBV plays an important role in the inflammation pathogenesis of liver,evaluation of epidemiology history and of treatment strategy. Chronic HBV infection is closely related to active transcription and persistence of covalently closed circular DNA(cccDNA) in the liver. The result of quantitative anti-HBc antibody examination shows a good correlation with cccDNA level so it is a potential index for comprehensive evaluation of HBV infectious diseases.

Key words: hepatitis B virus(HBV), covalently closed ciecular DNA, quantitative of hepatitis B core antibody, chronic infection

中图分类号:

R512.6

杜心怡, 毛小荣, 李俊峰. 抗-HBc定量测定在乙型肝炎病毒慢性感染性疾病中的应用[J]. 基础医学与临床, 2022, 42(5): 804-808.

DU Xin-yi, MAO Xiao-rong, LI Jun-feng. Application of anti-HBc quantitative examination in clinical management of chronic hepatitis B virus infection[J]. Basic & Clinical Medicine, 2022, 42(5): 804-808.

参考文献

[1] European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67: 370-398.
[2] Huang Q, Zhou B, Cai D, et al. Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients[J]. Hepatology, 2021, 73: 41-52.
[3] Kao JH, Jeng WJ, Ning Q, et al. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients[J]. Hepatol Int, 2021, 15: 833-851.
[4] Caviglia GP, Abate ML, Tandoi F, et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection[J]. J Hepatol, 2018, 69: 301-307.
[5] Song LW, Liu PG, Liu CJ, et al. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection[J]. Clin Microbiol Infect, 2015, 21: 197-203.
[6] Caviglia GP, Olivero A, Ciancio A, et al. Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection[J]. Diagn Microbiol Infect Dis, 2020, 96: 5.
[7] Ko C, Chakraborty A, Chou WM, et al. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels[J]. J Hepatol, 2018, 69: 1231-1241.
[8] Marchetti AL, Guo H. New insights on molecular mechanism of hepatitis B virus covalently closed circular DNA formation[J]. Cells, 2020, 9:2430.doi:10.3390/cells9112430.
[9] Zhang ZQ, Shi BS, Lu W, et al. Quantitative anti-HBc in liver pathological states in patients with chronic hepatitis B virus Infection[J]. Can J Infect Dis Med Microbiol, 2019, 2019:6545642.doi:10.1155/2019/6545642.
[10] Wang J, Yan X, Chen Y, et al. Characteristics of hepatitis B core antibody level in the natural history of chronic hepatitis B[J]. Discov Med, 2018, 26: 119-125.
[11] Li J, Zhang TY, Song LW, et al. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels[J]. Hepatol Res, 2018, 48: 133-145.
[12] Fan R, Sun J, Yuan Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues[J]. Gut, 2016, 65: 313-320.
[13] Chi H, Li Z, Hansen BE, et al. Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy[J]. Clin Gastroenterol Hepatol, 2019, 17: 182-191.
[14] Li MR, Zheng HW, Lu JH, et al. Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B[J]. Oncotarget, 2017, 8: 11063-11070.
[15] Li MR, Zheng HW, Ma SM, et al. Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-naïve CHB patients[J]. J Chin Med Assoc, 2018, 81: 1052-1059.
[16] Yang HC, Tsou HH, Pei SN, et al. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection[J]. J Hepatol, 2018, 69: 286-292.
[17] Matsubara T, Nishida T, Shimoda A, et al. The combination of anti-HBc and anti-HBs levels is a useful predictor of the development of chemotherapy-induced reactivation in lymphoma patients with resolved HBV infection[J]. Oncol Lett, 2017, 14: 6543-6552.
[18] Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis[J]. Hepatology, 2017, 66: 13-26.
[19] Yeh ML, Huang CF, Hsieh MH, et al. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals[J]. J Gastroenterol Hepatol, 2017, 32: 1754-1762.
[20] Dao DY, Hynan LS, Yuan HJ, et al. Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels[J]. Hepatology, 2012, 55: 676-684.
[21] Li J, Gong QM, Xie PL, et al. Prognostic value of anti-HBc quantification in hepatitis B virus related acute-on-chronic liver failure[J]. J Gastroenterol Hepatol, 2021, 36: 1291-1299.
[22] Li T, Wang SK, Zhou J, et al. Positive HBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of HBV-related HCC[J]. Liver Int, 2016, 36: 284-292.
[23] Yuan G, Zhou Y, Zhang H, et al. Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J]. Int J Clin Exp Med, 2015, 8: 13524-13531.
[24] Kim J, Kang W, Sinn DH, et al. Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea[J]. Korean J Intern Med, 2020, 35: 65-78.

抗-HBc定量测定在乙型肝炎病毒慢性感染性疾病中的应用

Application of anti-HBc quantitative examination in clinical management of chronic hepatitis B virus infection

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	亢必勃, 赵绒, 赵杨, 申焕君, 陈朝霞, 周云, 范超. 血浆B细胞趋化因子1和干细胞因子水平与HBV感染患者临床指标的关系[J]. 基础医学与临床, 2023, 43(2): 289-292.
[2]	戚婉蓉, 毛小荣, 李俊峰. 血液高凝状态在肝硬化中作用的研究进展[J]. 基础医学与临床, 2021, 41(3): 423-427.
[3]	张雪梅, 李俊峰, 毛小荣. 胆汁酸代谢在肝硬化并发症中的研究进展[J]. 基础医学与临床, 2021, 41(1): 103-107.
[4]	李京源李涛朱席琳伍晓盼刘英. ADAR1通过RNA编辑上调ZNF655表达并促进人肝癌细胞系HepG2中HBV复制[J]. 基础医学与临床, 2018, 38(3): 312-316.
[5]	张梦阳叶素素刘晓清许少侠周宝桐侍效春徐虹韩扬张丽帆邓国华. 经核苷（酸）类药物治疗的慢性乙型肝炎HBsAg定量分析[J]. 基础医学与临床, 2017, 37(6): 817-820.
[6]	周兰英蒋乐龙李定梅阎青于红缨姚志军向开敏. 慢性乙型肝炎患者外周血单个核细胞Toll样受体3的表达降低[J]. 基础医学与临床, 2013, 33(8): 1028-1031.
[7]	刘凤君刘丽蒋智刘聪唐红. 恩替卡韦抑制乙型肝炎病毒复制型小鼠体内病毒的复制[J]. 基础医学与临床, 2009, 29(10): 1017-1020.
[8]	李明皓, 范亮亮, 项荣. 内质网应激在丙肝病毒感染发病学中作用的研究进展[J]. 基础医学与临床, 2022, 42(2): 316-320.